NasdaqGS:IMVT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Immunovant's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMVT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: IMVT's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-11.1%

IMVT

3.5%

US Biotechs

-1.0%

US Market


1 Year Return

159.4%

IMVT

36.8%

US Biotechs

19.6%

US Market

Return vs Industry: IMVT exceeded the US Biotechs industry which returned 36.8% over the past year.

Return vs Market: IMVT exceeded the US Market which returned 19.6% over the past year.


Shareholder returns

IMVTIndustryMarket
7 Day-11.1%3.5%-1.0%
30 Day-11.8%4.8%2.3%
90 Day5.7%21.7%13.1%
1 Year159.4%159.4%39.0%36.8%22.3%19.6%
3 Yearn/a30.5%23.6%45.3%35.7%
5 Yearn/a43.9%33.0%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Immunovant's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Immunovant undervalued compared to its fair value and its price relative to the market?

11.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IMVT ($44.1) is trading below our estimate of fair value ($49.59)

Significantly Below Fair Value: IMVT is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: IMVT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IMVT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMVT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMVT is overvalued based on its PB Ratio (9.8x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is Immunovant forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

5.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMVT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMVT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMVT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if IMVT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if IMVT's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IMVT is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Immunovant performed over the past 5 years?

-51.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: IMVT is currently unprofitable.

Growing Profit Margin: IMVT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if IMVT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare IMVT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: IMVT has a negative Return on Equity (-18.1%), as it is currently unprofitable.


Next Steps

Financial Health

How is Immunovant's financial position?


Financial Position Analysis

Short Term Liabilities: IMVT's short term assets ($450.3M) exceed its short term liabilities ($12.8M).

Long Term Liabilities: IMVT's short term assets ($450.3M) exceed its long term liabilities ($2.7M).


Debt to Equity History and Analysis

Debt Level: IMVT is debt free.

Reducing Debt: IMVT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMVT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if IMVT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Immunovant current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMVT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMVT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMVT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMVT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMVT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Pete Salzmann (53 yo)

1.58yrs

Tenure

US$8,806,834

Compensation

Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer of Immunovant, Inc. since June 2019 and has been its Director since October 2019. Dr. Salzmann serves as Non-Independent ...


CEO Compensation Analysis

Compensation vs Market: Pete's total compensation ($USD8.81M) is above average for companies of similar size in the US market ($USD5.02M).

Compensation vs Earnings: Insufficient data to compare Pete's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Salzmann
CEO & Director1.58yrsUS$8.81m0.38%
$ 16.3m
Pamela Connealy
Chief Financial Officer1.17yrsUS$2.98mno data
Julia Butchko
Chief Development & Technology Officer1.25yrsno data0.0051%
$ 220.6k
Michael Elliott
Chief Scientific Officer0.42yrno datano data
Lauren Schrier
Vice President of Marketing1yrno datano data
Beverly Paperiello
Senior VP of Program Strategyno datano datano data
Alan Jacobs
VP & Head of Neurology Development0.42yrno datano data
Ann Daus
VP & Head of Global Quality0.42yrno datano data
Rita Jain
Chief Medical Officerno datano datano data

1.0yrs

Average Tenure

56yo

Average Age

Experienced Management: IMVT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Peter Salzmann
CEO & Director1.58yrsUS$8.81m0.38%
$ 16.3m
George Migausky
Independent Director1.08yrsUS$19.46k0%
$ 0
Andrew Fromkin
Independent Director1.25yrsUS$461.52k0.0047%
$ 203.8k
Atul Pande
Independent Director1.25yrsUS$454.23k0.0047%
$ 203.8k
Frank Torti
Chairperson of the Board1.58yrsUS$882.87k0.041%
$ 1.8m
Douglas Hughes
Independent Director1.25yrsUS$458.30k0.0047%
$ 203.8k
Eric Venker
Director0.92yrno datano data

1.3yrs

Average Tenure

53yo

Average Age

Experienced Board: IMVT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.4%.


Top Shareholders

Company Information

Immunovant, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunovant, Inc.
  • Ticker: IMVT
  • Exchange: NasdaqGS
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.317b
  • Shares outstanding: 97.89m
  • Website: https://www.immunovant.com

Number of Employees


Location

  • Immunovant, Inc.
  • 320 West 37th Street
  • New York
  • New York
  • 10018
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMVTNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDDec 2019

Biography

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that se...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/18 00:31
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.